Antonia Joussen (Charité, University Medicine Berlin) shares her advice on preserving the eye when treating patients with large tumours and shares the key take-home messages of her presentations at EURETINA 2019.
Questions:
1. How do you preserve eyes with large tumours?
2. What are the main take-home messages of your presentations at EURETINA 2019?
Support: No funding was received in the production of this video.
Trending Topic
Two ARVO 2026 abstracts highlight the continuing shift in retinopathy of prematurity (ROP) care, with longer-term trial data supporting the durability of intravitreal aflibercept and real-world registry data showing increasing national adoption of anti-VEGF therapy. Together, the findings suggest that anti-VEGF therapy is becoming an increasingly important part of ROP management, while reinforcing the need for structured follow-up and continued training in both injection-based and laser approaches.
At the ARVO 2026 Annual Meeting, DME remained a major focus, with multiple studies exploring how clinicians may extend treatment intervals, improve outcomes in suboptimal responders and target inflammatory pathways beyond VEGF. Across phase 2 and phase 3 trials, as well as real-world observational studies, key themes included long-term durability with faricimab, sustained-delivery approaches, and growing evidence supporting dual-pathway strategies that may help address the heterogeneity of DME in routine practice.
Designed for busy clinicians, these short, focused articles cut through theory to highlight what truly matters at the point of care including what works, what to watch for, and how to optimise outcomes in real-world settings.
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for ...
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with ...
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes ...
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about the problems with the clinical utility of vascular endothelial growth factor inhibitors and the issues around durability and ensuring good outcomes in ...
It was a pleasure to talk to Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) on her EURETINA course on rhegmatogenous retinal detachment repair. In this interview, she discussed the treatment options for rhegmatogenous retinal detachment. The instructional course entitled “Mechanisms ...
In this touchOPHTHALMOLOGY interview, Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) discussed techniques involved in retinal reattachment and shared the highlights from her EURETINA course on rhegmatogenous retinal detachment repair. The instructional course entitled “Mechanisms of Action in Rhegmatogenous Retinal ...
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a ...
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) discussed the findings of a study investigating the relationship between optical coherence tomography angiography and fluorescein angiography/indocyanine green angiography in AMD ...
Prof. Bart Leroy (Ghent University, Ghent, Belgium) joined touchOPHTHALMOLOGY in an interview to speak about RNA interference therapy and its advantages in treating inherited retinal diseases caused by CEP290 mutations. ‘RNA Interference Therapy for CEP290-IRD’ was presented at EURETINA 2022, 1–4 ...
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen's University of Belfast, Belfast, Northern Ireland) to ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
